Aug 12 (Reuters) - Experts in Prader-Willi Syndrome on Tuesday raised safety concerns over Neurocrine's drug Vykat XR, citing serious ‌adverse events reported in patients with the rare genetic ‌disorder. Food and Drug Administration's Adverse ​Event Monitoring System (AEMS) showed ‌seven reports of death linked to patients taking the drug as of July 31, 2026. The organizations said the reports were concerning and that patients and ‌families deserved transparency regarding the drug's safety ​profile. They stressed, however, that the reports ​do not establish a ​causal relationship between Vykat XR and the reported ‌outcomes. Advertisement AdvertisementAdvertisement Advertisement"The purpose of this new statement ​is not to ​discourage the use of VYKAT XR.